Embodiments of a spray-drying process for producing low aspect ratio particles of poly[(methyl methacrylate)-co-(methacrylic acid)] (PMMAMA) are disclosed. In some examples, at least 95% of PMMAMA-containing particles made by the process have an aspect ratio <10. The particles may further include an active ingredient and/or an excipient.

An implant for the control of parasites in livestock comprising an isoxazoline compound of Formula (I)

##STR00001## or salt or solvate thereof, wherein the implant comprises one or more pellets each of which comprises the isoxaxoline compound and a pharmaceutically acceptable excipient and a method of preventing or treating a parasite infestation using the same.

The present invention provides a method for safe and efficacious administration of esketamine.

Compositions for treating a sleep disorder or modifying or improving the sleep-wake cycle in a subject are disclosed herein. In some examples, the composition can comprise one or more sleep promoting active agents, one or more sleep quality active agents, one or more sleep recovery active agents, and optionally one or more next day active agents. The composition can provide an immediate burst release of the one or more sleep promoting active agents, a delayed burst or delayed sustained release of the one or more sleep quality active agents, a delayed burst or delayed sustained release of the one or more sleep recovery active agents, and a delayed burnt or delayed sustained release of the one or more next day active agents. The composition can be provided as a daily oral uni-dosage form. Methods of making and using the compositions are also provided.

The invention relates to pharmaceutical compositions comprising a PCSK9 inhibitor, such as an EGF(A) peptide, and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid. The invention further relates to processes for the preparation of such compositions, and their use in medicine.

Disclosed are a composition containing an aromatic heterocyclic compound in an amorphous form, and a preparation method therefore and a use thereof. Specifically, disclosed is a composition containing a compound of Formula (1) and a carrier, wherein the compound of formula (1) is in an amorphous form. The composition shows valuable properties in terms of in vivo absorption and bioavailability, and has the advantages of rapid absorption and high bioavailability, etc.

##STR00001##

The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention.

The present invention provides a drug composition comprising particles comprising a biodegradable or bioerodable polymer and a drug, a soluble, biodegradable or bioerodible excipient, a bulking agent and a reconstitution aid. The invention also provides a pharmaceutical formulation and a unit dosage form of the pharmaceutical formulation. The invention provides methods of treatment of a disease or condition accordingly. The invention also provides a drug composition for use in a cannulation device.

This invention relates to high drug load compositions of medium chain triglycerides (MCT), and to methods for treatment with such compositions at amounts effective to elevate ketone body concentrations so as to treat conditions associated with reduced neuronal metabolism, for example Alzheimer's disease.

Provided herein are pharmaceutical formulations of dry-powder bendamustine suitable for pharmaceutical use. Also provided are methods of producing dry-powder bendamustine. The pharmaceutical formulations can be used for any disease that is sensitive to treatment with bendamustine, such as neoplastic diseases.